by Bioblast Editor | Nov 24, 2020 | Biosimilars updates
Novartis released its annual report ‘Meet Novartis Management 2020’. In the report, Novartis announced that GP2411 (biosimilar denosumab candidate) has commenced Ph III trials. Novartis has also indicated it has planned launches for biosimilar adalimumab...
by Bioblast Editor | Sep 10, 2020 | Biosimilars updates
Neurology Advisor reported a new study indicates that natalizumab may be more effective than fingolimod or BRACETD in reducing relapses in patients with relapsing-remitting multiple sclerosis.
by Bioblast Editor | Nov 18, 2019 | Biosimilars updates
Polpharma commences dosing in Phase III trials of proposed natalizumab biosimilar.
by Bioblast Editor | Oct 13, 2019 | Biosimilars updates
Polpharma publishes details of upcoming phase III clinical trials of biosimilar natalizumab candidate. The study will involve approximately 260 patients with relapsing-remitting multiple sclerosis.
by Bioblast Editor | Sep 3, 2019 | Biosimilars Deals 2019, Biosimilars updates
Pfizer and Polpharma announce licensing deal for natalizumab biosimilar. Under the agreement, Polpharma will develop, manufacture and supply the product, while Sandoz will be responsible for commercialisation and distribution.
